A disease called Alzheimers disease, which affects the brain and body, is estimated to affect about one in 50 people, making it one of the world’s fastest-growing cancers.
It’s also one of many debilitating neurological disorders, including dementia, that affect the brain.
Alzheimers is thought to be caused by a genetic mutation that affects the way the body uses nerve cells.
It can cause the brain to die.
The disease, commonly known as AD, affects about one out of 50 people.
But a new study published in the Lancet medical journal suggests that, in some cases, it could be more prevalent.
Alzaheimer’s is the most common type of dementia, but it can affect up to 20% of people.
There are currently no effective treatments, according to the National Institute of Neurological Disorders and Stroke.
However, some new therapies are being developed.
A small trial published in Nature Medicine shows that taking a daily dose of the brain-derived neurotrophic factor, a protein, improved cognitive function in patients with early stage AD.
The team led by Dr. Thomas Bartsch, an associate professor of neurology at Stanford University, said the drug, a form of synthetic BDNF, could be used to treat the condition.
Alzeheimer’s patients often take drugs to boost their cognitive function.
The drug does not cure the disease.
However, the treatment may help patients who have had other brain diseases before and reduce the severity of the symptoms.
The trial included 11 people with mild-to-moderate cognitive impairment and 12 people with severe cognitive impairment.
The researchers then administered BDNF to the brains of the two groups and monitored their cognitive performance.
They also measured brain waves, blood flow, and other markers to see how their cognitive functions improved.
The study found that patients taking the drug fared better on cognitive tests.
However a second group took an anti-depressant drug, which the researchers said reduced their levels of the neurotrophic factors.
The drug was safe, but there were some concerns that patients might not benefit as much if they were on it for weeks.